Schellekens H - Search Results

1

Taking immunogenicity assessment of therapeutic proteins to the next level.

Büttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, Kramer D, Kropshofer H, Lloyd P, Lubiniecki A, Krause R, Mire-Sluis A, Platts-Mills T, Ragheb JA, Reipert BM, Schellekens H, Seitz R, Stas P, Subramanyam M, Thorpe R, Trouvin JH, Weise M, Windisch J, Schneider CK. Büttel IC, et al. Among authors: schellekens h. Biologicals. 2011 Mar;39(2):100-9. doi: 10.1016/j.biologicals.2011.01.006. Epub 2011 Feb 24. Biologicals. 2011. PMID: 21353596

2

Biosimilars need comparative clinical data.

Casadevall N, Thorpe R, Schellekens H. Casadevall N, et al. Among authors: schellekens h. Kidney Int. 2011 Sep;80(5):553. doi: 10.1038/ki.2011.164. Kidney Int. 2011. PMID: 21841836 Free article. No abstract available.

3

Immunogenicity of therapeutic proteins: the use of animal models.

Brinks V, Jiskoot W, Schellekens H. Brinks V, et al. Among authors: schellekens h. Pharm Res. 2011 Oct;28(10):2379-85. doi: 10.1007/s11095-011-0523-5. Epub 2011 Jul 9. Pharm Res. 2011. PMID: 21744171 Free PMC article. Review.

4

The immunogenicity of therapeutic proteins.

Schellekens H. Schellekens H. Discov Med. 2010 Jun;9(49):560-4. Discov Med. 2010. PMID: 20587346 Free article.

5

Factors influencing the immunogenicity of therapeutic proteins.

Schellekens H. Schellekens H. Nephrol Dial Transplant. 2005 Jun;20 Suppl 6:vi3-9. doi: 10.1093/ndt/gfh1092. Nephrol Dial Transplant. 2005. PMID: 15958824 Review.

6

Immunogenicity of therapeutic proteins: clinical implications and future prospects.

Schellekens H. Schellekens H. Clin Ther. 2002 Nov;24(11):1720-40; discussion 1719. doi: 10.1016/s0149-2918(02)80075-3. Clin Ther. 2002. PMID: 12501870 Review.

7

How to predict and prevent the immunogenicity of therapeutic proteins.

Schellekens H. Schellekens H. Biotechnol Annu Rev. 2008;14:191-202. doi: 10.1016/S1387-2656(08)00007-0. Biotechnol Annu Rev. 2008. PMID: 18606364 Review.

8

An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products.

Meager A, Dolman C, Dilger P, Bird C, Giovannoni G, Schellekens H, Thorpe R, Wadhwa M. Meager A, et al. Among authors: schellekens h. J Interferon Cytokine Res. 2011 Apr;31(4):383-92. doi: 10.1089/jir.2010.0113. Epub 2010 Dec 7. J Interferon Cytokine Res. 2011. PMID: 21138379

9

Immunogenicity of rDNA-derived pharmaceuticals.

Ryff JC, Schellekens H. Ryff JC, et al. Among authors: schellekens h. Trends Pharmacol Sci. 2002 Jun;23(6):254-6. doi: 10.1016/s0165-6147(02)02024-2. Trends Pharmacol Sci. 2002. PMID: 12084625 Review.

10

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.

van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EH, Schellekens H. van Meer PJ, et al. Among authors: schellekens h. MAbs. 2013 Sep-Oct;5(5):810-6. doi: 10.4161/mabs.25234. Epub 2013 Jun 6. MAbs. 2013. PMID: 23924803 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

325 results

Search Page

Filters